Articles > Popular publications > PR Newswire press releases > April-June 2003 > Wednesday, May 14

Article: Novuspharma SpA Announces Financial Results for the Three Months Ended 31 March 2003.

Article from:
PR Newswire
Article date:
May 14, 2003
Copyright

Novuspharma SpA (Nuovo Mercato: NOV.MI), a biopharmaceutical company focused on cancer, today announces financial results for the three months ended 31 March 2003 and an update on R&D in the first quarter. 

 
  Highlights: 
   -- Pivotal phase III trial continuing for pixantrone (BBR 2778) in 
  indolent non-Hodgkin's lymphoma (NHL) in combination with Rituxan 
  (rituximab). 
   -- Results of a phase I/II trial for pixantrone in the BSHAP combination 
  accepted for presentation at the International Society of Experimental 
  Haematology, on July 5-8. A large phase II trial for the BSHAP regimen 
  is due to start in Q3 2003. 
   -- Results of a phase ...

Read all of this article with a FREE trial

Related newspaper, magazine, and journal articles:

Article: Novuspharma SpA Announces Plans for Phase I ...
PR Newswire;  December 2, 2002 ;     700+ words ...BRESSO, Italy -- Novuspharma SpA (Nuovo Mercato: NOV.MI), a biopharmaceutical ... today announces plans to begin a phase I trial of pixantrone (BBR 2778 ... editors). Pixantrone is currently in phase III studies for the treatment of non ...

Article: NOVUSPHARMA SPA ANNOUNCES FINANCIAL RESULTS FOR THE ...
PR Newswire;  November 13, 2001 ;     700+ words ... ... transmitted on behalf of Novuspharma SpA. Co-founders and managers ... agreement Bresso, Italy - Novuspharma SpA (Nuovo Mercato: NOV ... commenced recruitment for a US Phase II combination study; US Phase III studies expected to ...

Article: Novuspharma SpA Announces Results of BBR 2778 Study ...
Business Wire;  June 24, 2002 ;     700+ words ... ... Neurological Society in Berlin Novuspharma SpA (Nuovo Mercato:NOV ... intercalating agent currently in Phase III clinical trials for ... to c.$3bn by 2004. Novuspharma SpA Novuspharma, based in ... has recently begun Phase III clinical trials in ...

Article: Novuspharma SpA Announces Financial Results for the ...
PR Newswire;  November 13, 2001 ;     700+ words ... ... Nov. 13 /PRNewswire/ -- Novuspharma SpA (Nuovo Mercato: NOV.MI ... commenced recruitment for a US Phase II combination study; US Phase III studies expected to begin by year end * BBR 2778 European Phase II trial results presented ...

Article: Novuspharma SpA Announces Results For The Third ...
Cancer Weekly;  December 18, 2001 ;     700+ words ... ... amp; NewsRx.net) -- Novuspharma SpA (NOV.MI) has reported financial ... commenced recruitment for a U.S. Phase II combination study; U.S. Phase III studies expected to begin by year end * BBR 2778 European Phase II trial results presented ...

Article: Novuspharma SpA Financial Results for the Ninth ...
PR Newswire;  October 20, 2003 ;     700+ words ...Novuspharma SpA (Nuovo Mercato: NOV.MI ... Procedure. * Results of a Phase II study for Pixantrone in ... preliminary positive results from a phase I combination trial for Pixantrone ... Novuspharma published results of a Phase II study for Pixantrone ...

Article: Novuspharma SpA results of BBR 2778 study show ...
Pain & Central Nervous System Week;  August 5, 2002 ;     700+ words ...2002 AUG 5 - (NewsRx.com & NewsRx.net) -- Novuspharma SpA (NOV.MI), a biotechnology company focused on cancer ... BBR 2778 is Novuspharma's intercalating agent currently in phase III clinical trials for the treatment of non-Hodgkin lymphoma ...

Article: Novuspharma SpA results of BBR 2778 study show ...
Drug Week;  August 9, 2002 ;     504 words ...2002 AUG 9 - (NewsRx.com & NewsRx.net) -- Novuspharma SpA (NOV.MI), a biotechnology company focused on cancer ... BBR 2778 is Novuspharma's intercalating agent currently in phase III clinical trials for the treatment of non-Hodgkin lymphoma ...

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!

Find articles, research, and archives